Although it only relatively recently caught on in the West, Traditional Chinese Medicine (TCM), is not new age; it’s old age. This time-tested medical science has been practiced for some 5,000 years in China. Indeed, in that country it’s a highly trusted form of conventional medicine, not an alternative feel-good science. For evidence of how seriously this form of folk medicine is taken, one only need look toward the growing number of Chinese drugmakers and biotech companies that are merging ancient herbal remedies with modern Western science to create drugs to treat everything from arthritis to impotence to cancer.

China Sky One Medical, Inc. (AMEX:CSY) specializes in Chinese medicine products and is gearing up to tap a growing share of China's multi-billion dollar drug market, about 20% of which is TCM pharmaceuticals. The Chinese pharmaceutical market has grown at an average rate of 15% annually over the past several years, and is projected to maintain double-digit growth over the next few years, making China the sixth-largest drug market by 2011, according to Research and Markets' China Pharmaceutical Logistics Industry Report, 2008.

Operating exclusively in China, through its subsidiaries Harbin Tian Di Ren Medical Science and Technology Company (TDR) and TDR’s subsidiaries, China sky develops, manufactures, markets and sells branded, over-the-counter plant- and herb-based pharmaceutical and medicinal products and nutritional supplements. The company’s primary products are external-use remedies based on traditional Chinese herbal medicine including creams, ointments, sprays, powders, skin patches and herbs. It also engages in tissue and stem cell research through TDR's wholly owned subsidiary, Harbin Tian Qing Biotech Application Company. In all, China Sky manufactures . . .

For access to the full article, you must be a registered member - it's FREE.